A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 15 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Jan 2019.